Advanced Accelerator Applications and NCI form clinical trial agreement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Advanced Accelerator Applications and NCI formed a clinical trial agreement: NCI plans to sponsor and conduct a study of Lutathera in patients with inoperable pheochromocytoma and paraganglioma.

Pheochromocytoma is a rare endocrine tumor originating in the adrenal glands. Paraganglioma is a tumor that is closely related to pheochromocytoma and originates from outside the adrenal glands. Both are considered orphan diseases.

Lutathera (lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue peptide currently in development for the treatment of gastro entero pancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera is a peptide receptor radionuclide therapy, which involves targeting carcinoid tumors with radiolabeled somatostatin analogue peptides. This compound has received orphan drug designation from the European Medicines Agency and the FDA.

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login